Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Avenue Therapeutics stock price, quote, forecast and news

ATXI
US05360L2051
A2JH92

Price

2.51
Today +/-
+0.15
Today %
+6.80 %
P

Avenue Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Avenue Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Avenue Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Avenue Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Avenue Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Avenue Therapeutics Stock Price History

DateAvenue Therapeutics Price
9/27/20242.51 undefined
9/26/20242.35 undefined
9/25/20242.24 undefined
9/24/20242.25 undefined
9/23/20242.39 undefined
9/20/20242.46 undefined
9/19/20242.61 undefined
9/18/20242.70 undefined
9/17/20242.76 undefined
9/16/20242.79 undefined
9/13/20242.81 undefined
9/12/20242.80 undefined
9/11/20242.90 undefined
9/10/20242.86 undefined
9/9/20243.02 undefined
9/6/20242.83 undefined
9/5/20242.80 undefined
9/4/20242.81 undefined
9/3/20242.79 undefined
8/30/20242.54 undefined

Avenue Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Avenue Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avenue Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avenue Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Avenue Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Avenue Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Avenue Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avenue Therapeutics’s growth potential.

Avenue Therapeutics Revenue, EBIT and net profit per share

DateAvenue Therapeutics RevenueAvenue Therapeutics EBITAvenue Therapeutics Net Income
2026e0 undefined-17.71 M undefined-4.07 M undefined
2025e0 undefined-15.5 M undefined-4.58 M undefined
2024e0 undefined-14.29 M undefined-9.28 M undefined
20230 undefined-14.54 M undefined-10.38 M undefined
20220 undefined-8.04 M undefined-3.55 M undefined
20210 undefined-3.74 M undefined-3.73 M undefined
20200 undefined-5.21 M undefined-5.15 M undefined
20190 undefined-26.27 M undefined-25.91 M undefined
20180 undefined-21.82 M undefined-21.55 M undefined
20170 undefined-11.42 M undefined-12.26 M undefined
20160 undefined-2.38 M undefined-3.18 M undefined
20150 undefined-4.84 M undefined-5.23 M undefined

Avenue Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e
000000000000
------------
------------
000000000000
-4-2-11-21-26-5-3-8-14-14-15-17
------------
-5-3-12-21-25-5-3-3-10-9-4-4
--40.00300.0075.0019.05-80.00-40.00-233.33-10.00-55.56-
7.47.45.99.11414.715.129.1141.2000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Avenue Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Avenue Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
0.010.221.782.678.753.133.766.711.78
000000000
000000000
000000000
000.391.850.170.110.110.140.07
0.010.222.174.538.923.253.876.851.85
000000000
000000000
000000000
000000000
000000000
000000000
000000000
0.010.222.174.538.923.253.876.851.85
                 
0.040.051.1000000
0.050.1138.9441.5874.9275.6380.4584.4692.51
-5.23-8.4-20.66-42.21-68.12-73.27-77-80.55-90.93
000000000
000000000
-5.14-8.2519.38-0.636.82.363.453.911.58
11.852.793.580.370.170.360.360.4
0.170.401.580.750.710.150.610.21
0.110.31001002.610.59
000000000
1.173.850000000
2.456.422.795.162.120.890.513.581.2
2.72.030000000
000000000
000000000
2.72.030000000
5.158.452.795.162.120.890.513.581.2
0.010.222.174.528.913.243.967.482.78
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Avenue Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Avenue Therapeutics's financial health and stability.

Assets

Avenue Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Avenue Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Avenue Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Avenue Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-5-3-12-21-25-5-3-3-10
000000000
000000000
1121-20000
3031100-41
000000000
000000000
0-1-6-18-26-4-3-7-9
-300000000
-30-10100-100-3
00-10100-100-3
000000000
41-2000000
003403505117
312803204107
---3.00--2.00----
000000000
0011-96-502-4
-3.9-1.63-6.8-18.22-26.26-4.61-3.75-7.6-9.45
000000000

Avenue Therapeutics stock margins

The Avenue Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avenue Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avenue Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Avenue Therapeutics's sales revenue. A higher gross margin percentage indicates that the Avenue Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Avenue Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Avenue Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avenue Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avenue Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avenue Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Avenue Therapeutics Margin History

Avenue Therapeutics Gross marginAvenue Therapeutics Profit marginAvenue Therapeutics EBIT marginAvenue Therapeutics Profit margin
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %

Avenue Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Avenue Therapeutics earnings per share therefore indicates how much revenue Avenue Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avenue Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avenue Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avenue Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avenue Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avenue Therapeutics Revenue, EBIT and net profit per share

DateAvenue Therapeutics Sales per ShareAvenue Therapeutics EBIT per shareAvenue Therapeutics Earnings per Share
2026e0 undefined0 undefined-2.85 undefined
2025e0 undefined0 undefined-3.2 undefined
2024e0 undefined0 undefined-6.49 undefined
20230 undefined-102.97 undefined-73.49 undefined
20220 undefined-276.39 undefined-122.06 undefined
20210 undefined-247.55 undefined-247.09 undefined
20200 undefined-354.63 undefined-350.41 undefined
20190 undefined-1,876.07 undefined-1,850.57 undefined
20180 undefined-2,397.36 undefined-2,367.91 undefined
20170 undefined-1,935.76 undefined-2,077.63 undefined
20160 undefined-321.22 undefined-429.32 undefined
20150 undefined-654.46 undefined-706.22 undefined

Avenue Therapeutics business model

Avenue Therapeutics Inc is a biotechnology company specializing in the development of pain relief and anesthesia medications. The company was founded in 2015 and has since brought several products to the market. The core business of Avenue Therapeutics is the development of medications for pain and chronic pain. The company works with various compounds that selectively block pain receptors in the brain, including opioid receptors and cannabinoid receptors. The company currently has several products in the pipeline in different stages of clinical development. These include AV001, an anesthetic based on fentanyl used for pain relief in traumatic injuries and surgeries, and AV002, a pain medication based on tramadol used for acute and chronic pain. Another product being developed by the company is AV003, a synthetic cannabinoid compound that can be used for pain relief, as well as the treatment of anxiety disorders and seizures. In addition to their therapeutic effectiveness, all Avenue Therapeutics products are designed to be less addictive than traditional opioid medications. This goal is achieved through targeted dosing and special formulations. The business model of Avenue Therapeutics is based on the research, development, and marketing of pain medications and anesthetics. This includes production, clinical development, regulatory approval, and marketing in the healthcare market. Avenue Therapeutics has a wide range of customers, including hospitals, medical practices, and healthcare facilities, as well as patients suffering from pain and chronic pain. The products are offered in the North American market and can be purchased directly from the manufacturer or through sales by external distributors and retailers. An important goal of the company is to expand its product portfolio through the development of new and innovative pain medications. Therefore, the company continuously invests in research and development and collaboration with other companies and institutions to discover new technologies and compounds. However, the market for pain medications and anesthetics is highly competitive, and Avenue Therapeutics faces a range of challenges. These include stringent regulatory requirements, high costs for clinical trials, and a constant challenge to discover new technologies and compounds. Despite these challenges, Avenue Therapeutics has achieved impressive growth and a strong position in the market for pain medications and anesthetics in recent years. The company is in a good position to continue developing innovative medications in the future and provide its customers with a wide portfolio of high-quality pain relief drugs. Please indicate if these answers are enough or if you need further clarification. Avenue Therapeutics is one of the most popular companies on Eulerpool.com.

Avenue Therapeutics SWOT Analysis

Strengths

Avenue Therapeutics Inc has several strengths that contribute to its success:

  • Strong financial position and robust funding, allowing for continued research and development initiatives.
  • Experienced management team with a deep understanding of the pharmaceutical industry.
  • Strategic partnerships with well-established pharmaceutical companies, providing access to resources and distribution networks.
  • Strong intellectual property portfolio, protecting the company's innovative drug formulations.

Weaknesses

Despite its strengths, Avenue Therapeutics Inc faces certain weaknesses:

  • Reliance on a limited product pipeline, making the company vulnerable to market fluctuations and competition.
  • Challenges in securing regulatory approval for new drugs, leading to potential delays in product launches.
  • High research and development costs, putting pressure on financial resources.
  • Limited brand recognition compared to larger pharmaceutical companies, impacting market penetration.

Opportunities

Avenue Therapeutics Inc can explore the following opportunities to drive growth:

  • Expansion into emerging markets, where there is a growing demand for affordable and accessible pharmaceutical products.
  • Investment in innovative technologies and drug delivery systems to enhance the company's product offerings.
  • Partnerships and collaborations with academic institutions to leverage research capabilities and access new scientific advancements.
  • Acquisition or licensing agreements with smaller biotech firms to expand the company's product portfolio.

Threats

Avenue Therapeutics Inc must monitor and address the following threats to mitigate potential risks:

  • Intense competition from well-established pharmaceutical companies, which may limit market share and pricing power.
  • Stringent regulatory requirements and evolving healthcare policies, leading to potential delays in product approvals and increased compliance costs.
  • Uncertainty in intellectual property protection, making the company susceptible to patent challenges and generic competition.
  • Fluctuating market dynamics and economic conditions, impacting consumer affordability and demand for pharmaceutical products.

Avenue Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Avenue Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Avenue Therapeutics shares outstanding

The number of shares was Avenue Therapeutics in 2023 — This indicates how many shares 141,200 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avenue Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avenue Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avenue Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avenue Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avenue Therapeutics Stock splits

In Avenue Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Avenue Therapeutics.

Avenue Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.07 -6.43  (-500.37 %)2024 Q2
3/31/2024-9.18 -15.4  (-67.76 %)2024 Q1
12/31/2023-7.65 4.5  (158.82 %)2023 Q4
9/30/2023-19.89 4.5  (122.62 %)2023 Q3
6/30/2023-22.19 -39  (-75.79 %)2023 Q2
3/31/2023-0.13 -1.35  (-918.1 %)2023 Q1
12/31/2022-0.15 0.26  (269.93 %)2022 Q4
9/30/2021-0.77 -0.75  (1.96 %)2021 Q3
6/30/2021-0.92 -0.9  (1.96 %)2021 Q2
3/31/2021-0.92 -0.9  (1.96 %)2021 Q1
1
2
3

Eulerpool ESG Scorecard© for the Avenue Therapeutics stock

Eulerpool World ESG Rating (EESG©)

15/ 100

🌱 Environment

16

👫 Social

22

🏛️ Governance

8

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Avenue Therapeutics list of shareholders

%
Name
Stocks
Change
Date
91.59441 % Davidow (Robert L)1,309,800-617,00012/11/2023
6.19895 % Citadel Advisors LLC88,64588,64512/31/2023
46.22769 % Sabby Management, LLC661,056661,05612/31/2023
3.64755 % Geode Capital Management, L.L.C.52,160-41112/31/2023
3.23727 % The Vanguard Group, Inc.46,293012/31/2023
248.06944 % Fortress Biotech Inc3,547,393413,5074/16/2024
24.49776 % Rosenwald (Lindsay A)350,31803/6/2024
2.13937 % State Street Global Advisors (US)30,593012/31/2023
2.00035 % Millennium Management LLC28,60528,60512/31/2023
17.55322 % Heights Capital Management, Inc.251,011-21,68912/31/2022
1
2
3
4
...
5

Avenue Therapeutics Executives and Management Board

Dr. Alexandra Maclean55
Avenue Therapeutics Chief Executive Officer, Director (since 2022)
Compensation 300,543
Mr. Neil Herskowitz66
Avenue Therapeutics Independent Director
Compensation 60,000
Dr. Jay Kranzler65
Avenue Therapeutics Chairman
Compensation 50,000
Mr. Curtis Oltmans59
Avenue Therapeutics Independent Director
Compensation 50,000
Ms. Faith Charles61
Avenue Therapeutics Independent Director
Compensation 31,250
1
2

Most common questions regarding Avenue Therapeutics

What values and corporate philosophy does Avenue Therapeutics represent?

Avenue Therapeutics Inc represents values of innovation, integrity, and patient-centered care in the pharmaceutical industry. The company is committed to developing and commercializing innovative therapies to address unmet medical needs. Their corporate philosophy revolves around scientific excellence, collaboration with key stakeholders, and a deep dedication to improving the lives of patients. By staying at the forefront of research and development, Avenue Therapeutics strives to deliver transformative solutions while adhering to the highest ethical standards. With a focus on delivering value to patients, healthcare providers, and shareholders, Avenue Therapeutics Inc aims to make a positive impact in the healthcare landscape.

In which countries and regions is Avenue Therapeutics primarily present?

Avenue Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Avenue Therapeutics achieved?

Avenue Therapeutics Inc has achieved significant milestones since its establishment. The company successfully completed a pivotal Phase 3 study for its lead product, intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. Additionally, Avenue Therapeutics Inc received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) which outlined certain requirements to support the New Drug Application (NDA) for IV tramadol. The company continues to work towards meeting these requirements and is committed to advancing the development of IV tramadol as a potential non-opioid treatment option for patients in need.

What is the history and background of the company Avenue Therapeutics?

Avenue Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of intravenous (IV) pain management medications. Founded in 2015, the company focuses on providing innovative treatment options for patients suffering from acute pain following surgery or medical procedures. Avenue Therapeutics Inc aims to improve the standard of care in pain management through its unique drug formulations and delivery methods. With a dedicated team of experts and a strong commitment to research and development, the company is actively working towards addressing the unmet needs in pain management and improving patient outcomes. Avenue Therapeutics Inc is poised to make a significant impact in the healthcare industry.

Who are the main competitors of Avenue Therapeutics in the market?

The main competitors of Avenue Therapeutics Inc in the market are pharmaceutical companies such as Pacira Pharmaceuticals, Mallinckrodt Pharmaceuticals, and Heron Therapeutics.

In which industries is Avenue Therapeutics primarily active?

Avenue Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Avenue Therapeutics?

The business model of Avenue Therapeutics Inc is focused on developing and commercializing intravenous (IV) tramadol, a potential non-opioid pain medication. Tramadol is a centrally acting analgesic that has been approved for the management of moderate to moderately severe pain. Avenue Therapeutics aims to address the unmet need for non-opioid pain relief options through the development and commercialization of IV tramadol. By leveraging their expertise and research in pain management, Avenue Therapeutics is committed to providing patients with effective and safer pain management alternatives while reducing the risks associated with opioid-related medications.

What is the P/E ratio of Avenue Therapeutics 2024?

The Avenue Therapeutics P/E ratio is -0.04.

What is the P/S ratio of Avenue Therapeutics 2024?

The Avenue Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Avenue Therapeutics?

The AlleAktien quality score for Avenue Therapeutics is 2/10.

What is the revenue of Avenue Therapeutics 2024?

The revenue cannot currently be calculated for Avenue Therapeutics.

How high is the profit of Avenue Therapeutics 2024?

The expected Avenue Therapeutics profit is -9.28 M USD.

What is the business model of Avenue Therapeutics

Avenue Therapeutics Inc. is an innovative pharmaceutical company specializing in the development and marketing of analgesics. The company focuses on the needs of patients requiring rapid pain relief, such as after surgeries or severe injuries. Its main product is Tramadol, an opioid analgesic used intravenously and as a supportive therapy for moderate to severe pain. Avenue Therapeutics aims to bring its products to market quickly through a combination of in-house development and acquisitions. It works closely with healthcare providers and utilizes a multi-channel marketing strategy. Research and development are also important components of the company's business model. Overall, Avenue Therapeutics is focused on meeting the pain relief needs of patients and aims to increase its market share through its diversified products and services.

What is the Avenue Therapeutics dividend?

Avenue Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Avenue Therapeutics pay dividends?

The dividend cannot currently be calculated for Avenue Therapeutics or the company does not pay out a dividend.

What is the Avenue Therapeutics ISIN?

The ISIN of Avenue Therapeutics is US05360L2051.

What is the Avenue Therapeutics WKN?

The WKN of Avenue Therapeutics is A2JH92.

What is the Avenue Therapeutics ticker?

The ticker of Avenue Therapeutics is ATXI.

How much dividend does Avenue Therapeutics pay?

Over the past 12 months, Avenue Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avenue Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Avenue Therapeutics?

The current dividend yield of Avenue Therapeutics is .

When does Avenue Therapeutics pay dividends?

Avenue Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avenue Therapeutics?

Avenue Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Avenue Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avenue Therapeutics located?

Avenue Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avenue Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avenue Therapeutics from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.

When did Avenue Therapeutics pay the last dividend?

The last dividend was paid out on 9/28/2024.

What was the dividend of Avenue Therapeutics in the year 2023?

In the year 2023, Avenue Therapeutics distributed 0 USD as dividends.

In which currency does Avenue Therapeutics pay out the dividend?

The dividends of Avenue Therapeutics are distributed in USD.

All fundamentals about Avenue Therapeutics

Our stock analysis for Avenue Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avenue Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.